A Study Comparing CoQ10 Levels While Taking 3 Different Statins
NCT ID: NCT01660191
Last Updated: 2017-01-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
134 participants
INTERVENTIONAL
2011-12-31
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients
NCT00631189
STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose Ranges
NCT00654537
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants
NCT05176314
Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia
NCT00683618
Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)
NCT00653744
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Previous studies have shown that Pitavastatin may not affect CoQ10 levels as other statins do, while still lowering cholesterol.
In this study, investigators intend to compare the plasma levels of CoQ10 in patients taking 3 different FDA-approved statins, in equipotent doses.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pitavastatin 4mg
Pitavastatin 4mg tablet by mouth once daily for 12 weeks
Atorvastatin 20mg
Rosuvastatin 5mg
Atorvastatin 20mg
Atorvastatin 20mg tablet by mouth once daily for 12 weeks
Pitavastin 4mg
Rosuvastatin 5mg
rosuvastatin 5 mg
rosuvastatin 5 mg tablet by mouth once daily for 12 weeks
Pitavastin 4mg
Atorvastatin 20mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pitavastin 4mg
Atorvastatin 20mg
Rosuvastatin 5mg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing to discontinue use of all lipid-altering doses fo medication or supplements for the duration of the study
Exclusion Criteria
* History of diabetes mellitus or documented fasting blood glucose \>125mg/dl or HbA1c \>6.4%
* History of coronary artery disease
* history of chronic renal or hepatic disease
* known sensitivity of intolerance to a statin
* persistent elevated liver enzymes or CPK (\>3 x upper normal limit)
* currently taking CoQ10 supplements and unable discontinue for duration of study
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kowa Pharmaceuticals America, Inc.
INDUSTRY
Eli Lilly and Company
INDUSTRY
University of Kansas Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Patrick Moriarty, MD, FACP, FACC
Director, Atherosclerosis & LDL-Apheresis Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patrick M Moriarty, MD, FACC
Role: PRINCIPAL_INVESTIGATOR
University of Kansas Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Kansas Medical Center
Kansas City, Kansas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12943
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.